Descriptive Regional Subanalysis of a Real-World Study in Patients with Type 2 Diabetes Treated with Gliclazide MR During Fasting: DIA-RAMADAN

Hassanein, Mohamed; Sifri, Saud Al; Shaikh, Shehla; Raza, Syed Abbas; Akram, Javed; Rudijanto, Achmad; Shaltout, Inass; Fariduddin, .; Mohamed, Wan Mohd Izani Bin Wan; Awadi, Fatheya Al; Durocher, Alexandra; Cortese, Viviana; Alessa, Thamer

doi:10.1007/s13300-021-01067-1

Cited by 5 publications

(7 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Four reports in 2021 addressed the antidiabetic pharmacological therapies during Ramadan. Two were related to the DIA-Ramadan study, 15,16 and the other two were systematic reviews and metanalysis. 17,18 Raza et al 15 assessed the safety and effectiveness of gliclazide modified release (MR) of 60 mg in people with controlled or suboptimal-controlled T2DM.…”

Section: Pharmacological Treatmentmentioning

confidence: 99%

“…Thirteen adverse events unrelated to gliclazide MR were reported during the study period. Also, Hassanein et al 16 reported another subgroup analysis from the same study (DIA-RAM-ADAN) by considering three geographically and culturally different regions. Data were captured at inclusion 6 to 8 weeks prior to Ramadan, during Ramadan (4.5 weeks), and 4 to 6 weeks after Ramadan.…”

Section: Pharmacological Treatmentmentioning

confidence: 99%

“…Four reports in 2021 addressed the antidiabetic pharmacological therapies during Ramadan. Two were related to the DIA-Ramadan study, 15 16 and the other two were systematic reviews and metanalysis. 17 18…”

Section: Highlights Of the Literaturementioning

confidence: 99%

See 2 more Smart Citations

Ramadan Fasting and Diabetes (2021): The Year in Review

Beshyah

Hafidh

Kenz

et al. 2022

Journal of Diabetes and Endocrine Practice

View full text Add to dashboard Cite

Introduction The literature on the impact of Ramadan fasting (RF) on diabetes is widely spread in many journals. This makes it not readily accessible to those interested in the subject. We aimed to provide a narrative overview of the global literature production in 1 year (2021) on diabetes and RF. Materials and Methods This was a narrative, nonsystematic review of the international literature from a single major medical online database (i.e., PubMed) during the year 2021. The search term “Ramadan fasting AND Diabetes” was used, and the relevant literature was narrated in a concise thematic account. Results The publications spanned a vast array of topics related to diabetes and RF, including epidemiology, assessments of safety and efficacy profiles of older and newer diabetes therapies, hypoglycemia, diabetes education, use of advanced technology for the treatment, and monitoring and impact on pregnancy. Some reports covered the interaction of Ramadan and the novel coronavirus disease 2019 (COVID-19) in relationship to diabetes. Professional concerns, patients' perspectives, and telemedicine's role in RF were also addressed. Conclusion The current narration presents this year's literature on the safety of fasting practices, care models, and patients' experiences and perspectives. Work should continue on comprehensive assessments for the interplay of diabetes and RF under different settings. Particular attention should focus on the roles of newer antidiabetic medicines and advanced technology for safer fasting practices.

show abstract

Section: Pharmacological Treatmentmentioning

confidence: 99%

Section: Pharmacological Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Ramadan Fasting and Diabetes (2021): The Year in Review

Beshyah

Hafidh

Kenz

et al. 2022

Journal of Diabetes and Endocrine Practice

View full text Add to dashboard Cite

show abstract

“…Patients receiving gliclazide MR with a baseline BMI of ≥ 25 kg/m 2 lost 0.9–2.2 kg in the EASYDia study [ 65 ]. In the DIA RAMADAN study, the average weight loss in the overall study population was 0.5 kg [ 43 ], but was highest (0.7 kg) in patients residing in the Middle East [ 66 ]. In the ADVANCE trial, an average gain of only 0.1 kg was reported after 5 years of intensive glucose control with gliclazide MR [ 45 ].…”

Section: Establishing Early Glycaemic Control In Patients With Diabetesmentioning

confidence: 99%

Management of Diabetes and Hypertension within the Gulf Region: Updates on Treatment Practices and Therapies

et al. 2022

Self Cite

View full text Add to dashboard Cite

Cardiovascular disease (CVD) is a leading cause of death globally, driven by the high rates of risk factors, such as diabetes and hypertension. As the prevalence of these risk factors is particularly high in the Gulf region, better diagnosis and management of type 2 diabetes (T2D) and hypertension has the potential to dramatically reduce adverse cardiovascular outcomes for individuals in that part of the world. This article provides a summary of presentations made during the EVIDENT summit, a virtual symposium on Evidence in Diabetes and Hypertension, held in September 2021, including a review of the various guidelines for both T2D and hypertension, as well as recent findings relevant to the safety and efficacy for therapies relating to these conditions. Of relevance to the Gulf region, the risk of hypoglycaemia with sulfonylureas during Ramadan was reviewed. For the management of T2D, sulfonylureas have been a long-standing medication used to achieve glycaemic control; however, differences have emerged between early and later generations, with recent studies suggesting improvements in the safety profiles of late-generation sulfonylureas. For patients with hypertension, incremental therapy changes are recommended to reduce the risk of cardiovascular complications that are associated with increasing blood pressure. For first-line therapy, angiotensin-converting enzyme inhibitors (ACEi), such as perindopril, have been demonstrated to reduce the risk of cardiovascular and all-cause mortality. The addition of calcium channel blockers and diuretics to ACEi has been shown to be effective in patients with poorly controlled hypertension. The different renin–angiotensin–aldosterone system inhibitors are reviewed, and the benefit of combination therapies, including amlodipine and indapamide in patients with difficult-to-control hypertension, is investigated. The benefits of lifestyle modifications for these patients are also discussed, with important clinical considerations that are expected to inform patient management in daily clinical practice.

show abstract

“…The current prevalence of DM in countries such as Bahrain, Saudi Arabia, Kuwait, Oman, Qatar, and United Arab Emirates (UAE) ranges from 8 to 27% [2][3][4][5]. At this moment, there are more than 1 billion Muslims around the world, mainly located in the Asia-Pacific region, Sub-Saharan Africa, and the Middle East/North Africa [6,7]. However, the number of patients with DM, particularly type 2 DM (T2DM), is expected to increase dramatically in the coming years.…”

Section: Introductionmentioning

confidence: 99%

A Real-World Study in Patients with Type 2 Diabetes Treated with Gliclazide Modified Release during Fasting in Gulf Cooperation Council Countries: An Analysis from the International DIA-RAMADAN Study

Hassanein

Sifri²,

Awadi

et al. 2022

Dubai Diabetes Endocrinol J

Self Cite

View full text Add to dashboard Cite

Introduction: The safety and effectiveness of gliclazide modified release (MR) in patients with type 2 diabetes mellitus (T2DM) who fasted during Ramadan were previously published. Here, we carried out a regional analysis among patients living in Gulf Cooperation Council (GCC) countries. Patients and Methods: DIA-RAMADAN was a real-world, observational, international, noncomparative study conducted in nine countries that included >1200 T2DM adults receiving gliclazide MR for at least 90 days before inclusion. The study comprised 2 visits: at inclusion, 6–8 weeks before the start of Ramadan (V0) and 4–6 weeks after the end of Ramadan (V1). The primary endpoint was the proportion of patients reporting ≥1 symptomatic hypoglycemic event as collected using a patient diary. Changes in HbA1c, fasting plasma glucose (FPG), and weight were also analyzed. This manuscript represents data collected in GCC countries (Kuwait, Saudi Arabia, and United Arab Emirates). Results: Data from 161 patients were analyzed: mean (SD) age 56.8 (10.6) years, 30.4% women, body mass index 29.1 (3.7) kg/m2, T2DM disease duration 6.7 (3.3) years, baseline HbA1c 7.9% (0.8). The proportions of patients reporting ≥1 symptomatic hypoglycemic event or confirmed hypoglycemia during Ramadan were 4.3% and 0.6%, respectively. No cases of severe hypoglycemia were reported. Significant reductions in main variables were observed before the start of Ramadan (V0) and 4–6 weeks after the end of Ramadan (V1): HbA1c (from 7.9 [0.8] to 7.6 [0.7]%; p value <0.001), FPG (from 143.5 [24.3] to 137.9 [25.2] mg/dL; p value = 0.031), and weight (from 79.0 [73.0–86.0] to 78.0 [72.0–85.0] kg; p value = 0.018). Conclusions: These real-world data indicate that patients with T2DM treated with gliclazide MR during Ramadan in the selected GCC countries have a low risk of hypoglycemia and maintain glycemic control and weight while fasting.

show abstract

Descriptive Regional Subanalysis of a Real-World Study in Patients with Type 2 Diabetes Treated with Gliclazide MR During Fasting: DIA-RAMADAN

Cited by 5 publications

References 28 publications

Ramadan Fasting and Diabetes (2021): The Year in Review

Ramadan Fasting and Diabetes (2021): The Year in Review

Management of Diabetes and Hypertension within the Gulf Region: Updates on Treatment Practices and Therapies

A Real-World Study in Patients with Type 2 Diabetes Treated with Gliclazide Modified Release during Fasting in Gulf Cooperation Council Countries: An Analysis from the International DIA-RAMADAN Study

Contact Info

Product

Resources

About